Volume | 22,429 |
|
|||||
News | - | ||||||
Day High | 0.398999 | Low High |
|||||
Day Low | 0.3666 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Galmed Pharmaceuticals Ltd | GLMD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.3963 | 0.3666 | 0.398999 | 0.3874 | 0.3851 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
155 | 22,429 | $ 0.3781802 | $ 8,482 | - | 0.26 - 7.80 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:58:57 | 1 | $ 0.436 | USD |
Galmed Pharmaceuticals Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
655.2k | 1.68M | - | 0 | -6.91M | -4.11 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Galmed Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLMD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.3949 | 0.40 | 0.3352 | 0.3814675 | 50,195 | -0.0075 | -1.90% |
1 Month | 0.3352 | 0.44 | 0.3301 | 0.3764027 | 258,919 | 0.0522 | 15.57% |
3 Months | 0.35 | 0.4688 | 0.30 | 0.3542597 | 213,283 | 0.0374 | 10.69% |
6 Months | 0.395 | 0.47 | 0.26 | 0.3715232 | 195,784 | -0.0076 | -1.92% |
1 Year | 4.80 | 7.80 | 0.26 | 1.94 | 228,814 | -4.41 | -91.93% |
3 Years | 49.50 | 61.20 | 0.26 | 17.15 | 169,879 | -49.11 | -99.22% |
5 Years | 116.40 | 121.50 | 0.26 | 34.78 | 153,996 | -116.01 | -99.67% |
Galmed Pharmaceuticals Description
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. |